Background: Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant.
melanoma skin cancer), CVD, or other major chronic illness; and were willing to forgo outside use of study medications. A total of 39 876 women were willing, eligible, and adherent during a 3-month placebo run-in (Figure 1) . Randomization took place from 30 April 1993 through 24 January 1996 in blocks of 16 participants within 5-year age groups. Written informed consent was obtained from all participants. The trial was approved by the Institutional Review Board of Brigham and Women's Hospital and was monitored by an external data and safety monitoring board.
Trial Follow-up
Participants were sent annual supplies of monthly calendar packs containing active agents or placebo. At 6 and 12 months and then yearly, participants were mailed questionnaires seeking information on study drug adherence, adverse effects, nonstudy aspirin use, clinical end points, and risk factors. Study medications and end point ascertainment were continued in a blinded fashion through the scheduled end of the trial in March 2004. During the posttrial period, women were sent annual questionnaires identical to those used during the intervention period. However, monthly calendar packs were no longer mailed. Questions about the use of nonstudy aspirin were identical to those used during the trial period, as were questions about adverse effects, clinical end points, and various risk factors.
Study Outcomes
When a cancer case or cardiovascular event was reported during the trial or posttrial period, written consent for medical record review was requested from the participant (or next of kin if the participant was deceased) and medical records were obtained from hospitals or treating physicians. All relevant information was reviewed by an end points committee comprising physicians blinded to 
Context
Whether long-term use of alternate-day, low-dose aspirin affects cancer risk is unclear.
Contribution
This observational follow-up of a large randomized trial involving several thousand female health professionals found that long-term use of alternate-day, low-dose (100-mg) aspirin was associated with reduced colorectal cancer incidence and increased risk for gastrointestinal bleeding and peptic ulcers.
Caution
Not all women received extended follow-up. Information on gastrointestinal bleeding and polyps was obtained only from self-report during extended follow-up, and ascertainment bias was possible.
Implication
Long-term use of alternate-day, low-dose aspirin may reduce risk for colorectal cancer but increase risk for gastrointestinal bleeding in healthy women.
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Original Research Alternate-Day, Low-Dose Aspirin and Cancer Risk treatment assignment. Only confirmed end points are included in this analysis. The primary cancer end point for the WHS was any invasive cancer, excluding nonmelanoma skin cancer. Incidences of breast, colorectal, and lung cancer were secondary end points. Reports of cancer were confirmed by pathology or cytology reports or, rarely, were based on strong clinical and radiologic or laboratory marker evidence (for example, elevated CA-125 level). Cardiovascular end points were confirmed as previously described (15) , and a National Death Index search was conducted when cause of death was unconfirmed. End point review is complete for 95% of reported cancer cases, 95% of myocardial infarctions, and 94% of strokes. The confirmation rate among participants with records is 82% for cancer, 61% for myocardial infarction, and 68% for stroke. Of all deaths, 60% have a cause confirmed by medical records, 78% are confirmed or have death certificates, and 85% are confirmed and have death certificates or National Death Index reports.
Women were asked on annual questionnaires whether they were diagnosed with a colon polyp, peptic ulcer, or gastrointestinal bleeding. During the active intervention, medical records were reviewed from a small random subset (n ϭ 558) of women reporting incident colon polyps; of these, 295 (53% [55% in the aspirin group and 51% in the placebo group]) were confirmed to be adenomatous polyps (10). Self-reported information on colonoscopy or sigmoidoscopy was collected at 1 year; at 9 years; at the end of the trial; and in posttrial years 1, 2, 3, and 5, with the questions at 9 years and the end of the trial asking about procedures since randomization. Incident gastrointestinal bleeding or peptic ulcers were confirmed by supplementary questionnaires during the active intervention period only. Reports of gastrointestinal bleeding or peptic ulcers were collected intermittently during posttrial follow-up and were not confirmed. Use of nonstudy aspirin was assessed using the same questions as those used during the trial period.
Statistical Analysis
Primary analyses were intention-to-treat. We used Kaplan-Meier survival curves to estimate incidence over time and the log-rank test to compare curves. We used Cox proportional hazards models (16), adjusted for age and vitamin E assignment, to estimate the hazard ratio (HR) and 95% CI when comparing women randomly assigned to aspirin versus placebo over the entire follow-up. Tests for proportionality included an interaction of aspirin with the logarithm of time. Effects during the trial (active intervention) and posttrial (extended follow-up) periods were estimated separately using the counting process style of input to the Cox regression model (17) .
We conducted analyses for total, breast, colorectal, lung, and other site-specific types of cancer. For comparison with published meta-analyses (8, 9), we also grouped sites into broad categories (8) , including gastrointestinal tract (esophagus, stomach, pancreas, biliary tract, liver, small bowel, colon, or rectum), urinary tract (kidney, ureter, bladder, or urethra), respiratory tract (lung, pleura, larynx, pharynx, or nasopharynx), reproductive (breast, endometrium, ovary, cervix, or vagina), and hematologic (lymphoma, leukemia, or myeloma) and examined metastatic cancer (9) (defined as distant bloodborne metastases) and adenocarcinoma, separately and combined. For completeness, we also examined cardiovascular end points and total deaths.
To determine whether aspirin assignment affected screening and detection of colon polyps, we examined proportions screened and all self-reports of colon polyps over time by aspirin group. We also examined self-reported gastrointestinal bleeding events and peptic ulcers over time by aspirin assignment.
Because a subset of participants opted out of extended posttrial follow-up, we examined baseline characteristics and intervening trial events, such as gastrointestinal symptoms, cancer screening, and study pill adherence, by aspirin group among those who opted in. To adjust for differences in opt-out response by intervention, we used inverse probability weighting in a sensitivity analysis to adjust for any imbalances (17) . We constructed a propensity score for opting in for further follow-up that included the characteristics described previously as well as aspirin assignment and its interaction with adherence, which served as the denominator for the weights. Stabilized weights were formed by including as the numerator a model with aspirin assignment only (18) .
In addition, we examined cancer outcomes after the trial by posttrial aspirin use and randomized aspirin intervention. We defined posttrial aspirin use as more than 3 days per month, as determined from the first (or second if the first was missing) observational questionnaire, and developed a propensity score for posttrial aspirin use. We again used inverse probability weighting, which has been found to have low bias and minimal error for confounder adjustment (19) . All analyses were conducted in SAS, version 9.2 (SAS Institute, Cary, North Carolina). All P values are 2-sided.
Role of the Funding Source
The National Heart, Lung, and Blood Institute and the National Institutes of Health provided funding for the study. The funding sources had no role in the design, conduct, or analysis of our study or the decision to submit the manuscript for publication.
RESULTS
At the time of the first posttrial questionnaire in 2005-2006, 1875 women (4.7%) had died since randomization (949 [4.8%] in the aspirin group vs. 926 [4.6%] in the placebo group; P ϭ 0.58) (Figure 1 . The mean age of the participants at randomization was 55 years; 54% were postmenopausal, and 13% were current smokers. Baseline characteristics did not differ by randomized aspirin assignment ( Table 1) . Among those who opted in for continued follow-up, baseline characteristics did not differ between randomized groups. Information on study aspirin use was reported by 99% of surviving women at year 2, 96% at year 4, and 95% at year 8. During the trial, use of study medication (aspirin or placebo) was consistently lower by about 1% in the aspirin group though follow-up (Appendix Figure 1 , available at www.annals.org) (10). In the final year of active intervention, 64% of participants in the aspirin group and 65% in the placebo group had used at least two thirds of the study medication. Women in both groups took the study pills for a median of 9 years (25th, 75th percentiles: 4, 11 years). Information on nonstudy aspirin use during the trial was reported by 98% of surviving women at year 2, 96% at year 4, and 92% at year 8. Nonstudy aspirin use for more than 3 days per month was similar between groups, with a median of 3 years among those who took it.
Among participants who opted in for posttrial followup, 96%, 95%, and 94% of surviving women provided information on aspirin use on the first, third, and fifth observational questionnaires, respectively. Use of posttrial nonstudy aspirin for at least 3 days per month was higher in the randomized aspirin group, reaching 46% in the aspirin group and 43% in the placebo group at year 15. Participants who used posttrial aspirin did so for a median of 3 years (25th, 75th percentiles: 2, 5 years). Nonaspirin nonsteroidal anti-inflammatory drugs were used by 20% of women at the end of the trial and 28% at the Original Research Alternate-Day, Low-Dose Aspirin and Cancer Risk end of posttrial follow-up, and use was similar between groups. During the 18-year follow-up, 5071 incident malignant cancer cases were confirmed, including 2070 breast, 451 colorectal, and 431 lung cancer cases ( Table 2) . Total cancer remained balanced between groups overall (16-year incidence, 0.127 and 0.132 in the aspirin and placebo groups, respectively; HR, 0.97 [95% CI, 0.92 to 1.03]; P ϭ 0.31) (Figure 2, A) , as did breast cancer (16-year incidence, 0.054 and 0.056 in the aspirin and placebo groups, respectively; HR, 0.98 [CI, 0.90 to 1.07]; P ϭ 0.65) (Figure 2, B) . We found an overall imbalance in colorectal cancer (16- Table 1 , available at www.annals.org). Survival curves suggested that the difference emerged after 10 years (Figure 2, C) . Although the interaction with the logarithm of time did not reach statistical significance (P ϭ 0.066), the difference in effect in the trial and posttrial periods was statistically significant (P ϭ 0.012) (posttrial HR, 0.58 [CI, 0.42 to 0.80]; P Ͻ 0.001). There were no apparent interactions with baseline characteristics (Appendix Table 2 , available at www.annals.org). We found no overall differences in lung cancer ( Figure 2, D) ; the slight reduction seen during the trial balanced out during the posttrial follow-up.
We found no differences in incidence of other cancer types, cancer deaths, or overall deaths (Appendix Table 1 ). When cancer types were grouped into broader categories (8) (Appendix Table 3 , available at www.annals.org), there was a difference in gastrointestinal cancer (16-year incidence, 0.016 and 0.019 in the aspirin and placebo groups, respectively; HR, 0.83 [CI, 0.72 to 0.97]; P ϭ 0.021). We found an interaction with time (P ϭ 0.015) (Appendix Figure 2 , available at www.annals.org), with a posttrial HR of 0.64 (CI, 0.49 to 0.82; P Ͻ 0.001).
We found an overall reduction in metastatic cancer that did not reach statistical significance (HR, 0.88 [CI, 0.77 to 1.00]; P ϭ 0.055) (Appendix Table 4 , available at www.annals.org). Although there was no significant deviation from proportionality, effects in the posttrial period were larger for metastatic cancer (HR, 0.81 [CI, 0.65 to 1.01]; P ϭ 0.063) and metastatic adenocarcinoma (HR, 0.73 [CI, 0.56 to 0.96]; P ϭ 0.025) but not for adenocarcinoma (Appendix Figures 3 to 5 , available at www.annals .org).
For CVD, the reduction in stroke seen in the trial period was reduced (Appendix Table 5 , available at www .annals.org), and there was no difference in major CVD or CVD death.
We saw more self-reported gastrointestinal bleeding events in the aspirin group during overall follow-up (16-year incidence, 0.085 and 0.075 in the aspirin and placebo groups, respectively; HR, 1.14 [CI, 1.06 to 1.22]; P Ͻ 0.001) ( Table 3) . The between-group difference was restricted to the trial period, with no further posttrial difference (P ϭ 0.79) (Appendix Figure 6 , available at www .annals.org). Only 6 deaths overall had gastrointestinal hemorrhage listed as a confirmed cause (3 each in the aspirin and placebo groups). Overall rates of self-reported peptic ulcer were also higher (16-year incidence, 0.077 and 0.065 in the aspirin and placebo groups, respectively; HR, 1.17 [CI, 1.09 to 1.27]; P Ͻ 0.001). The difference was again restricted to the trial period, with no further posttrial differences (P ϭ 0.26), although cumulative incidence re- Colon polyps were reported by 10 332 women, with no between-group differences overall (HR, 1.00 [CI, 0.96 to 1.04]; P ϭ 0.94) or during (P ϭ 0.31) or after the trial (P ϭ 0.27) ( Table 3 and Appendix Figure 8 , available at www.annals.org). We found few differences in reported endoscopies between groups during and after the trial (Appendix Table 6 , available at www.annals.org). When we restricted analyses to participants having endoscopy at least once during overall follow-up, we found no substantial change in effect for polyps or colorectal cancer.
Several between-group differences in events or conditions occurred during the trial, including gastrointestinal symptoms and adherence to study medication. Appendix Table 7 (available at www.annals.org) presents the propensity score for women who opted in for further follow-up. This group was more likely to adhere to medication during the trial and to have had gastrointestinal bleeding and screening endoscopies. It was also younger and less likely to be black, current smokers, nondrinkers, or past hormone therapy users. However, inverse probability weighting led to little change in the estimated effects overall or after the trial (Appendix Table 8 , available at www.annals.org). The estimated HR for aspirin and colorectal cancer remained 0.80 (CI, 0.66 to 0.97; P ϭ 0.021) over all follow-up and 0.58 (CI, 0.41 to 0.81; P ϭ 0.002) after the trial.
In further analyses, we examined the effects of aspirin according to posttrial use as well as random assignment. Compared with participants in the placebo group who did not start regular aspirin use, those in the placebo group who used aspirin had a 21% higher posttrial rate of colorectal cancer (HR, 1.21 [CI, 0.81 to 1.80]) (Appendix (Figure 3, top) , and those who continued to use aspirin after the trial had a 43% lower rate (HR, 0.57 [CI, 0.35 to 0.93]), although differences between the latter 2 groups were not statistically significant. Posttrial observational use, however, was positively associated with many risk factors for cancer (Appendix Table 10 , available at www.annals.org), including age, body mass index, and alcohol use. Women who had more screening procedures during the trial were also more likely to use aspirin after the trial, as were women in the aspirin group (but not the placebo group) who were adherent to study medication. When inverse probability weighting was used to adjust for these factors, the estimates remained consistent, with a reduction in colorectal cancer with longer-term aspirin use (Figure 3 [bottom] and Appendix Table 9 ). The increase among women who used aspirin in the placebo group was somewhat attenuated (HR, 1.17 [CI, 0.77 to 1.77]), whereas the estimated effects in the other 2 groups were largely unchanged.
DISCUSSION
At the end of the 10-year active intervention in the WHS, there was no difference in overall, colorectal, and other site-specific cancer by randomized aspirin group (10). The WHS was specifically designed to study effects on cardiovascular and cancer outcomes and had the same detailed collection of cancer outcomes, adverse effects, and screening procedures in extended follow-up. After a median follow-up of 18 years, a difference in colorectal cancer by randomized aspirin group emerged.
Recent literature supports a delayed effect of aspirin on cancer. Rothwell and colleagues (5-9) conducted metaanalyses of long-term effects of aspirin on cancer outcomes using trials of aspirin and CVD. In the British Doctors' and UK-TIA (United Kingdom Transient Ischaemic Attack) trials (7), allocation to 300 mg of aspirin per day reduced colorectal cancer after a latency of 10 years, with greater differences for proximal colon cancer (5). These beneficial findings extended to mortality at various cancer sites (6) , incident cancer at various sites (8) , and metastatic cancer and adenocarcinoma (9) . The strongest difference in these and other data was for gastrointestinal cancer. A recent trial of aspirin among patients with the Lynch syndrome (hereditary nonpolyposis colon cancer) found no difference during the initial mean 29-month intervention period but a longer-term 37% reduction in colon cancer over an average of 56 months (20) . Previous meta-analyses were limited to trials of daily aspirin, thus excluding the WHS, the largest trial of aspirin to date. We found similar long-term differences in cancer incidence, particularly colorectal cancer, with an HR of 0.80 compared with 0.76 in the meta-analysis (5). The effects of aspirin on CVD and bleeding seem to be more immediate, with attenuation of the randomized effect after aspirin is stopped. This is consistent with effects on the aggregation of platelets, which have a high turnover (21) . Aspirin may affect carcinogenesis through the cyclooxygenase-2 (COX-2) pathway (22) , which may require larger doses and a shorter dosing interval because of the rapid resynthesis of the enzyme in nucleated cells (21) . The WHS data, however, suggest that even low doses on alternate days could play a role in carcinogenesis, at least in the colon. A potential platelet-mediated mechanism for low-dose and even alternate-day aspirin has been hypothesized (23) . Permanent inactivation of platelet COX-1 could inhibit COX-2 upregulation in adjacent cell types in the intestinal mucosa at sites of mucosal injury, where platelets are likely to be recruited and activated. The induction of COX-2 and its downstream signaling could lead to reduced apoptosis and increased cell proliferation and angiogenesis. Other mechanisms, including non-COXdependent pathways, have been hypothesized (24) , although exact mechanisms have not been determined. A recent study raised the intriguing possibility that aspirin therapy increases survival primarily among patients with mutated-PIK3CA colorectal cancer (25) . This suggests that the PIK3CA mutation in colorectal cancer may serve as a predictive biomarker and that phosphatidylinositol 3-kinase-related pathways may play a role in aspirin's apparent effect on cancer.
The delayed differences in cancer outcomes by aspirin assignment may indicate an effect in the early stages of carcinogenesis, requiring a long latent period, especially at low doses. Alternative explanations are that increased bleeding leads to more endoscopy and early polyp removal. However, rates of colonoscopy or sigmoidoscopy were similar among groups in the WHS, and we found no difference in reported colon polyp occurrence over time. Furthermore, the greatest effect was seen in the proximal colon, which is less affected by sigmoidoscopy. Even if reduced cancer is caused by increased endoscopy and polyp removal due to symptoms, the net clinical effect seems to be a reduction in colorectal cancer.
A limitation of the current analysis is that posttrial information on gastrointestinal bleeding, peptic ulcers, and polyps was from self-report only. Not all polyp reports were reviewed, and none were reviewed in the observational follow-up. The confirmation rate for the reviewed reports was only 53% (10). Endoscopy was irregular and could be influenced by increased bleeding or gastrointestinal symptoms. Because trials of polyp recurrence that used a regular screening protocol have suggested lower rates with aspirin use (4), lower polyp incidence may be balanced by increased polyp detection in the WHS. However, this question cannot be answered definitively except by a long-term trial that includes regular screening colonoscopy, which would be difficult and expensive.
Other limitations include the option to opt out of posttrial follow-up. Women who remained in posttrial follow-up were more likely to have had endoscopies, which may have led to the slight posttrial uptick in rates of colorectal cancer seen in the placebo group (Figure 2, C) , which could be due to ascertainment bias. Because there was little difference between randomized groups, however, the randomized comparisons continue to be valid and are similar in adjusted and unadjusted analyses. Adherence to aspirin assignment during the trial was also imperfect. Crossover after the intervention probably diluted the posttrial effect as in the other trials examined. In analyses of posttrial use, however, women who continued to take aspirin continued to have lower rates of colorectal cancer. Posttrial observational aspirin use was influenced by many factors related to cancer incidence and diagnosis, and these latter analyses could still be subject to unmeasured confounding even after inverse probability weighting.
What are the implications of these findings for recommendations for aspirin use? Although aspirin is clearly protective in the secondary prevention of CVD, its effects are more limited in primary prevention (26) . The U.S. Preventive Services Task Force (27) recommends aspirin in women aged 55 to 79 years only when potential benefit outweighs potential harm. With more evidence for longterm effects in carcinogenesis, recommendations might be reconsidered. Over the 18-year study, there were 53 net fewer cancer cases (47 colorectal and 56 gastrointestinal) in the aspirin group compared with 48 fewer cases of CVD (47 strokes), which may extrapolate to 84 cases (66 strokes) if aspirin use had continued. Aspirin's adverse effects, however, cannot be forgotten. Even the WHS's low dose led to a net increase of 193 reported gastrointestinal bleeding events and 214 reported peptic ulcers, although some were minor. Relative risks for confirmed bleeding events were higher during the intervention period (15) . A recent study examining the net benefit of aspirin use concluded that aspirin could not be recommended for primary prevention
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Whether new results about long-term benefits for cancer will tip the balance in favor of aspirin remains to be determined. Irregularities over time are due to intermittent collection of these events after the trial. Irregularities over time are due to intermittent collection of these events after the trial. Irregularities over time are due to intermittent collection of these events after the trial. 
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